OBI Pharma, Inc., was founded in 2002. Its focus is on the ‘Unmet Medical Needs’ in challenging diseases throughout the world, such as Cancer & Infectious Diseases. OBI strives to improve health and the quality of life through innovative and cost-effective therapeutics.
OBI’s core competence is its R&D expertise in developing novel cancer and infectious disease therapies. The company uses its proprietary OPopS™ drug discovery platform to build a ground-breaking pipeline. OBI also works in close collaboration with prestigious research institutes, including Academia Sinica of Taiwan and the Memorial Sloane-Kettering Cancer Center of the US.
The company’s flagship product in development is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. The on-going Phase 2/3 multinational, randomized controlled trial for metastatic breast cancer (ClinicalTrials.gov Identifier: NCT01516307) was launched in 2011. OBI is also devoted to developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian. The company is the license holder for DIFICID™ in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea.
OBI is listed on Taiwan’s GreTai Securities Market Exchange as an Emerging Company (Stock code: 4174). It has established wholly-owned subsidiaries in the US and China. The company is led by a management team with a track record of success in new drug development and commercialization.
OBI Pharma, Inc.
Telephone：+886-2-2655-8799
Fax：+886-2-2655-8798
Address：Ste W1907, 19F, #3, Park St, Nankang Software Park,
Taipei, 11503, TAIWAN
Dr Michael Chang, founder and chairman of OBI Pharma, shares the history of his company’s beginnings and highlights the current progress of its innovative immune-oncology pipeline. Dr Chang goes on…
In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug…
The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development…
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively representing a number of cutting-edge raw materials from Europe, the US, and Japan. Stanley Huang is the…
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland China, in 2016 Taiwan’s government introduced the New Southbound Policy (NSP).…
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which are sparking global interest and attention – iXensor being a chief example. The company’s patented technology…
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned company to being acquired by private equity firm Nexus Point Capital. Yang goes on to…
United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform…
James Chiu, GM of Fresenius Kabi Taiwan, discusses the affiliate’s portfolio offering of parenteral and enteral nutrition in Taiwan as well as its move towards biosimilars. In addition, Chiu highlights…
Shuhei Sekiguchi, recently-appointed managing director of Janssen Taiwan, discusses how his vast experience in marketing and sales will help him in this new role, Janssen´s market outlook for Taiwan, its…
The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each…
G-SYN Biomedical Technology is a company dedicated to resolving problems occurring from cell hypoxia. Dieter Chang, the company’s founder introduces the firm, why they decided to focus on hypoxia, their…
Philip Chen, chairman of the Taipei Exchange, discusses the capital market condition, elaborates on the significance of biotech, and shares the competitive advantages of innovation companies listing on TPEx. Chen…
Danny Liao, CEO of Taiwanese diagnostics firm Skyla discusses the reason behind splitting from parent company Lite-On, the thinking behind a move from information technology (IT) into medical diagnostics and…
The Southern Taiwan Science Park (STSP)’s Chen-Kang Su discusses how STSP has played a key role in bringing innovation to Taiwan, how collaborations between academic institutions and industry are helping…
See our Cookie Privacy Policy Here
